Applicants will be prioritised based on their alignment to the fund’s objectives:

1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

Applications are welcome from companies developing highly innovative products such as:

• complex medicines such as advanced therapies and nucleic acid therapies, non-biological complex medicines and medicines that require complex delivery mechanisms
• innovative medical technologies such as nanomedicine applications in imaging, sensing, diagnosis, and delivery through medical devices, 5G enabled devices, smarter pacemakers and 3D printed devices
• diagnostics such as ‘breathalysers’ for the early detection of inflammatory and infectious diseases and ‘lab on a chip’

In addition, we particularly welcome applications that include the adoption of innovative process technologies, such as:

• flexible manufacturing enabling product switching
• scalable manufacturing
• novel manufacturing processes
• technologies that will minimise your impact on the environment
• continuous manufacturing, both for commercial scale and clinical trials manufacturing
• digital twins, which harness the power of data analytics and modelling to optimise manufacturing processes